Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Regan Jennifer A.; Cao Yun; Dispenza Melanie C.; Ma Shuo; Gordon Leo I.; Petrich Adam M.; Bochner Bruce S.

首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

【24h】

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

机译：伊布鲁替尼，一种用于治疗淋巴抑制性疾病的Bruton的酪氨酸激酶抑制剂，消除了Aeroallergen皮肤测试和嗜碱性激活测试反应性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of Allergy and Clinical Immunology》 |2017年第3期|共6页
作者
Regan Jennifer A.; Cao Yun; Dispenza Melanie C.; Ma Shuo; Gordon Leo I.; Petrich Adam M.; Bochner Bruce S.;
展开▼
作者单位

Northwestern Univ Feinberg Sch Med Dept Med Div Allergy Immunol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Med Div Allergy Immunol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Med Div Allergy Immunol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Med Div Hematol Oncol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Med Div Hematol Oncol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Med Div Hematol Oncol Chicago IL 60611 USA;

Northwestern Univ Feinberg Sch Med Dept Med Div Allergy Immunol Chicago IL 60611 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity [J] . Regan Jennifer A., Cao Yun, Dispenza Melanie C., The Journal of Allergy and Clinical Immunology . 2017,第3期

机译：伊布鲁替尼，一种用于治疗淋巴抑制性疾病的Bruton的酪氨酸激酶抑制剂，消除了Aeroallergen皮肤测试和嗜碱性激活测试反应性
2. Basophil activation test compared to skin prick test and fluorescence enzyme immunoassay for aeroallergen-specific Immunoglobulin-E [J] . Faisal M Khan, Aito Ueno-Yamanouchi, Bazir Serushago, Allergy, Asthma & Clinical Immunology . 2012,第1期

机译：嗜碱性粒细胞活化试验与皮肤点刺试验和荧光酶免疫测定法相比，对气敏原特异性免疫球蛋白E的影响
3. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies [J] . Tillman Benjamin F., Pauff James M., Satyanarayana Gowri, European Journal of Haematology . 2018,第4期

机译：对沥青酪氨酸激酶抑制剂Ibrutinib治疗血液学恶性肿瘤的系统评价
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. Bruton's tyrosine kinase regulates NF-κB activation and B cell survival by B cell receptor and BAFF-R [D] . Shinners, Nicholas Paul 2007

机译：布鲁顿酪氨酸激酶通过B细胞受体和BAFF-R调节NF-κB活化和B细胞存活
6. Basophil activation test compared to skin prick test and fluorescence enzyme immunoassay for aeroallergen-specific Immunoglobulin-E [O] . Faisal M Khan, Aito Ueno-Yamanouchi, Bazir Serushago, 2012

机译：嗜碱性粒细胞活化试验与皮肤点刺试验和荧光酶免疫测定法相比对气敏原特异性免疫球蛋白E的影响
7. Administration of two doses of an oral, irreversible inhibitor of Bruton’s tyrosine kinase (BTK) to food allergic adults abrogates skin test responses and eliminates IgE-mediated basophil activation ex vivo [O] . Melanie C. Dispenza, Jacqueline A. Pongracic, Anne Marie Singh, 2018

机译：施用两剂的口腔，不可逆抑制剂的Bruton的酪氨酸激酶（BTK）到食物过敏成人废除皮肤测试响应并消除了IgE介导的嗜碱性粒细胞活化以外
8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

机译：针对癌症治疗的选定药物遗传学测试的系统评价：CYp2D6用于乳腺癌中的他莫昔芬，KRas用于结肠直肠癌中的抗EGFR抗体，以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告

Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

著录项

相似文献

相关主题

期刊订阅